You are here: Industry Insights > IPF

News List

BenevolentAI and AstraZeneca expand drug discovery partnership Pharmaceutical-Technology
January 17, 2022
The companies collaborated initially in 2019 to use AI and machine learning to develop new therapies for CKD and IPF.
BenevolentAI achieves second major collaboration milestone with novel idiopathic pulmonary fibrosis target selected for AstraZeneca's portfolio prnasia
December 17, 2021
BenevolentAI, a leading clinical-stage AI drug discovery company, announced that AstraZeneca has added a novel target for idiopathic pulmonary fibrosis (IPF), discovered using BenevolentAI's platform, to its drug development portfolio.
Insilico Medicine Announces the Preclinical Candidate for Kidney Fibrosis Discovered Using End-to-End Artificial Intelligence Engine prnasia
August 05, 2021
Insilico Medicine announced that its AI-powered drug discovery platform had delivered the preclinical candidate ("PCC") for kidney fibrosis.
Daewoong, first-in-class PRS-inhibitor for Idiopathic Pulmonary Fibrosis(IPF) shows promising result in early stage clinical test prnasia
May 28, 2021
Daewoong Pharmaceutical of South Korea has announced the promising clinical results of DWN12088, which is being developed as a first-in-class Prolyl-tRNA Synthetase(PRS) inhibitor for idiopathic pulmonary fibrosis (IPF) .
GenScript ProBio Enters Collaboration with Singapore's Experimental Drug Development Centre to Develop Anti-Fibrosis Therapeutic Antibody Programme prnasia
April 21, 2021
GenScript Biotech Corporation's biopharmaceutical CDMO segment, GenScript ProBio announced a collaboration with the Experimental Drug Development Centre (EDDC), Singapore's national platform for drug discovery and development, on an anti-fibrosis ...
United Therapeutics Receives Orphan Drug Designation for Treprostinil for Idiopathic Pulmonary Fibrosis americanpharmaceuticalreview
December 30, 2020
United Therapeutics announced the United States Food and Drug Administration (FDA) has granted orphan drug designation to treprostinil for the treatment of patients with idiopathic pulmonary fibrosis (IPF).
Vicore Pharma recruits the first patient in the phase 2 proof-of-concept study in idiopathic pulmonary fibrosis pharmaceutical-business-review
November 18, 2020
Vicore Pharma Holding AB (publ), a pharmaceutical company dedicated to developing innovative medicines for rare lung disorders, announces that the first patient in the phase II idiopathic pulmonary fibrosis (IPF) study has been recruited in India.
Bridge Biotherapeutics terminates collaboration agreement with Boehringer pharmaceutical-technology
November 11, 2020
Bridge Biotherapeutics and Boehringer Ingelheim have mutually agreed to terminate their previously signed collaboration and licence agreement to develop BBT-877.
Cipla launches Nintib (Nintedanib) to treat Idiopathic Pulmonary Fibrosis expresspharma
October 22, 2020
Cipla has launched generic Nintedanib for the treatment of Idiopathic Pulmonary Fibrosis (IPF). Available as 100 mg and 150 mg capsules, it will be marketed under the brand name Nintib.
BDR Pharma launches Nintenib (Nintedanib) to treat idiopathic pulmonary fibrosis in India expresspharma
October 21, 2020
BDR Pharma announced the launch of 100 mg and 150 mg Nintedanib under the brand name Nintenib for the treatment of Idiopathic Pulmonary Fibrosis (IPF).

Previous page 1 2 Next page